Vitamin D for COVID-19 on Trial: An Update on Prevention and Therapeutic Application

  • William B. Grant
    Correspondence
    Address correspondence to Dr William B. Grant, Sunlight, Nutrition, and Health Research Center, P.O. Box 641603, San Francisco, CA 94164-1603.
    Affiliations
    Sunlight, Nutrition, and Health Research Center, San Francisco, California
    Search for articles by this author
  • Ronan Lordan
    Affiliations
    Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

    Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
    Search for articles by this author
Published:October 11, 2021DOI:https://doi.org/10.1016/j.eprac.2021.10.001
      The results of a pilot, randomized, placebo-controlled, double-blind clinical trial of calcifediol calcifediol {25-hydroxyvitamin D3 [25(OH)D3]} treatment in 106 COVID-19 patients in Iran are presented in an article in this issue.
      • Maghbooli Z.
      • Sahraian M.A.
      • Jamalimoghadamsiahkali S.
      • et al.
      Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood neutrophil-to-lymphocyte ratio marker of disease severity in hospitalized patients with COVID-19: a pilot multicenter, randomized, placebo-controlled, double-blinded clinical trial.
      The primary significant effects of calcifediol treatment were an increase in lymphocyte percentage and a decrease in the ratio of neutrophils to lymphocytes in the patients. In addition, there were modest trends for hospitalization, intensive care unit duration, needing ventilator assistance, and mortality in the calcifediol group compared to the placebo group. This commentary reviews what is known about vitamin D in preventing and treating COVID-19, in order to put the article by Maghbooli et al
      • Maghbooli Z.
      • Sahraian M.A.
      • Jamalimoghadamsiahkali S.
      • et al.
      Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood neutrophil-to-lymphocyte ratio marker of disease severity in hospitalized patients with COVID-19: a pilot multicenter, randomized, placebo-controlled, double-blinded clinical trial.
      in perspective.

      Abbreviations:

      IU (international unit), 25(OH)D (25-hydroxyvitamin D)
      To read this article in full you will need to make a payment
      AACE Member Login
      AACE Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Maghbooli Z.
        • Sahraian M.A.
        • Jamalimoghadamsiahkali S.
        • et al.
        Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood neutrophil-to-lymphocyte ratio marker of disease severity in hospitalized patients with COVID-19: a pilot multicenter, randomized, placebo-controlled, double-blinded clinical trial.
        Endocr Pract. 2021; 27: 1242-1251
        • Grant W.B.
        • Lahore H.
        • McDonnell S.L.
        • et al.
        Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths.
        Nutrients. 2020; 12: 988
        • Entrenas Castillo M.
        • Entrenas Costa L.M.
        • Vaquero Barrios J.M.
        • et al.
        Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study.
        J Steroid Biochem Mol Biol. 2020; 203: 105751
        • Lordan R.
        Notable developments for vitamin D amid the COVID-19 pandemic, but caution warranted overall: a narrative review.
        Nutrients. 2021; 13: 740
        • Ghosh S.K.
        • Weinberg A.
        Ramping up antimicrobial peptides against severe acute respiratory syndrome coronavirus-2.
        Front Mol Biosci. 2021; 8: 620806
        • Kaufman H.W.
        • Niles J.K.
        • Kroll M.H.
        • Bi C.
        • Holick M.F.
        SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels.
        PLoS One. 2020; 15e0239252
        • Meftahi G.H.
        • Jangravi Z.
        • Sahraei H.
        • Bahari Z.
        The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging".
        Inflamm Res. 2020; 69: 825-839
        • AlSafar H.
        • Grant W.B.
        • Hijazi R.
        • et al.
        COVID-19 disease severity and death in relation to vitamin D status among SARS-CoV-2-positive UAE residents.
        Nutrients. 2021; 13: 1714
        • Charoenngam N.
        • Shirvani A.
        • Reddy N.
        • Vodopivec D.M.
        • Apovian C.M.
        • Holick M.F.
        Association of vitamin D Status with hospital morbidity and mortality in adult hospitalized patients with COVID-19.
        Endocr Pract. 2021; 27: 271-278
        • Petrelli F.
        • Luciani A.
        • Perego G.
        • Dognini G.
        • Colombelli P.L.
        • Ghidini A.
        Therapeutic and prognostic role of vitamin D for COVID-19 infection: a systematic review and meta-analysis of 43 observational studies.
        J Steroid Biochem Mol Biol. 2021; 211: 105883
        • Annweiler C.
        • Beaudenon M.
        • Simon R.
        • et al.
        Vitamin D supplementation prior to or during COVID-19 associated with better 3-month survival in geriatric patients: extension phase of the GERIA-COVID study.
        J Steroid Biochem Mol Biol. 2021; 213: 105958
        • Yildiz M.
        • Senel M.U.
        • Kavurgaci S.
        • Ozturk F.E.
        • Ozturk A.
        The prognostic significance of vitamin D deficiency in patients with COVID-19 pneumonia.
        Bratisl Lek Listy. 2021; 122: 744-747
        • Rawat D.
        • Roy A.
        • Maitra S.
        • Shankar V.
        • Khanna P.
        • Baidya D.K.
        Vitamin D supplementation and COVID-19 treatment: a systematic review and meta-analysis.
        Diabetes Metab Syndr. 2021; 15: 102189
        • Bandeira L.
        • Lazaratti-Castro M.
        • Binkley N.
        Clinical aspects of SARS-CoV-2 infection and vitamin D.
        Rev Endocr Metab Disord. 2021; : 1-5
        • Charoenngam N.
        • Shirvani A.
        • Holick M.F.
        Vitamin D and its potential benefit for the COVID-19 pandemic.
        Endocr Pract. 2021; 27: 484-493
        • Lordan R.
        • Rando H.M.
        • Consortium C.-R.
        • Greene C.S.
        Dietary supplements and nutraceuticals under investigation for COVID-19 prevention and treatment.
        mSystems. 2021; 6 (e00122-21)

      Linked Article